Previously, immature overall survival results of the NRG Oncology GY018 (NRG-GY018) trial suggested that the use of the ...
At about 4 years of follow-up, first-line treatment with lenvatinib and pembrolizumab continued to confer a benefit over sunitinib monotherapy in patients with advanced renal cell carcinoma. Updated ...
Please provide your email address to receive an email when new articles are posted on . Researchers observed no significant PFS or OS benefit with pembrolizumab-olaparib vs. pembrolizumab-chemotherapy ...
A single-arm multicentre phase 2 trial conducted at five UK centres enrolled 48 patients with advanced CCGC between March 2019 and October 2021, with data collected until July 2024. Participants ...
At a median follow-up of about 2.5 years, enfortumab vedotin plus pembrolizumab continued to improve progression-free survival and overall survival. First-line treatment with enfortumab vedotin and ...
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company", 6990.HK) announced today that the results of the Phase III clinical study OptiTROP-Lung05, evaluating the company's trophoblast ...
Urothelium is the term for the mucous membrane that lines the urinary tract. This includes the renal pelvis, ureter, urinary bladder and the upper part of the urethra. In the vast majority of cases, ...
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company", 6990.HK) announced today that the results of the Phase III clinical study OptiTROP-Lung05 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results